SELLAS Life Sciences Group has reported positive results from its pivotal Phase 3 REGAL trial, with its investigational cancer vaccine galinpepimut-S (GPS) demonstrating a statistically significant overall survival benefit in patients with acute myeloid leukemia (AML).
The randomized study met its primary endpoint, showing a 41% reduction in the risk of death among pat...